Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tablet
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Vulvovaginal Candidiasis
Conditions
Recurrent Vulvovaginal Candidiasis
Trial Timeline
Oct 21, 2019 → Nov 29, 2021
NCT ID
NCT04029116About Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tablet
Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tablet is a phase 3 stage product being developed by Scynexis for Recurrent Vulvovaginal Candidiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT04029116. Target conditions include Recurrent Vulvovaginal Candidiasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04029116 | Phase 3 | Completed |
Competing Products
20 competing products in Recurrent Vulvovaginal Candidiasis